



**Jeremy Ahouse, CSAP, PhD**  
**VP Alliances | Merus, N.V.**

Merus, a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, uses its proprietary Biclonics® technology to develop novel bispecific antibodies.

Jeremy is responsible for establishing Merus' alliance function and managing a broad research and clinical collaboration with Incyte and other current and future partners. Jeremy has, since 1999, worked in pharmaceutical and biotech research and clinical collaborations with Celgene, Novartis, ImmunoGen, Vantage and Millennium.

Jeremy has served on the board of ASAP and helped to establish the CA-AM and CSAP exams. He contributed to the ASAP best practices guide.

He earned his PhD in immunology and biophysics, and held an HHMI post-doc in Developmental Genetics. He trained as a mediator and negotiator at Harvard's Program on Negotiation and has a keen interest in multiparty agreements and in how working with diverse teams helps research and drug development.